

Supplementary Material 1

Table S1. The list of primers used in this study.

Gene	Forward	Reverse
GAPDH	5'-GGAGCGAGATCCCTCCAAAAT-3'	5'-GGCTGTTGTCATACTTCTCATGG -3'
MYO6	5'-TGGGACAAGACCACCTCATGT-3'	5'-CCGGCTCCTGATTCTCCAGA-3'
AR	5'-CCAGGGACCATGTTTTGCC-3'	5'-CGAAGACGACAAGATGGACAA-3'
MYO6-shRNA#1	5'-CCGGTAGTGGAATACTGGATATTTCTCGAGAAATATCCAGTATTCCCCTA TTTTTG-3'	5'-AATTCAAAAATAGTGGGAATACTGGAT ATTTCTCGAGAAATATCCAGTATTCCCAC TA-3'
MYO6-shRNA#2	5'-CCGGGTGAATCCAGAGATAAGTTTACTCGAGTAACTTATCTCTGGATTCAC TTTTTG-3'	5'-AATTCAAAAAGTGAATCCAGAGATAAG TTTACTCGAGTAACTTATCTCTGGATTC AC-3'
AR-shRNA#1	5'-CCGGCCTGCTAATCAAGTCACACATCTCGAGATGTGTGACTTGATTAGCAGG TTTTTG-3'	5'-AATTCAAAAACCTGCTAATCAAGTCAC ACATCTCGAGATGTGTGACTTGATTAGCA GG-3'
AR-shRNA#2	5'-CCGGCGCGACTACTACAACCTTTCCACTCGAGTGGAAAGTTGTAGTAGTCGCG TTTTTG-3'	5'-AATTCAAAAACGCGACTACTACAACCTT TCCACTCGAGTGGAAAGTTGTAGTAGTCG CG-3'
MYO6-99P	5'-ACTGCACAGTCACAGTATCCAG-3'	5'-CTTGTTCTTCCCATGGCGAAAC-3'
MYO6-P1	5'-CTAGCTAGCactgcggcgtgcacgtcac-3'	
MYO6-P2	5'-CGGGGTACCgaagcagaggttcagcgagcc-3'	
MYO6-P3	5'-CGGGGTACCacaagacatttaagtggttg-3'	
MYO6-P4	5'-CGGGGTACCcagggattgcttgaggccaag-3'	
MYO6-P5	5'-CGGGGTACCagtttagtattaaatccaaattg-3'	
MYO6-P6	5'-CGGGGTACCgttttagtgaattctaaaacatc-3'	
MYO6-P7	5'-CGGGGTACCcgcaaccgccacgcagcctc-3'	
MYO6-P8	5'-CGGGGTACCggcaaaaggccgtttcgcc-3'	
MYO6-mutation	5'-gcgcgacacatggttctgggtccccgcgcggag-3'	5'-caggaacctgtgtccgcgttggcgccagcgaggctgc-3'
LAMA1	5'-GTGATGGCAACAGCGCAA-3'	5'-GACCCAGTGATATTCTCTCCCA-3'
BIRC3	5'-TTTCCGTGGCTCTTATTCAAACT-3'	5'-GCACAGTGGTAGGAACTTCTCAT-3'
CAPN2	5'-GTTCTGGCAATACGGCGAGT-3'	5'-CTTCGGCTGAATGCACAAAGA-3'
SHC3	5'-TCATAGCGAATCACCACATGC-3'	5'-CTCTGCGATTAACAGGGTCTT-3'
FYN	5'-ATGGGCTGTGTGCAATGTAAG-3'	5'-GAAGCTGGGGTAGTGCTGAG-3'
PAK1	5'-CAGCCCCCTCCGATGAGAAATA-3'	5'-CAAAACCGACATGAATTGTGTGT-3'
ITGA9	5'-AAAGTGCTGAACCTTACGGAC-3'	5'-TACCACATCAATGGTGGACGG-3'
ITGB8	5'-ACCAGGAGAAGTGTCTATCCAG-3'	5'-CCAAGACGAAAGTCACGGGA-3'
FLNC	5'-CTGGGCGATGAGACAGACG-3'	5'-GCGGATGGAACCTTGCGGTA-3'
RELN	5'-ACATCTACAAGTGTTCAAGGCATC-3'	5'-TGGTTACCAAACCTGGTGGTCA-3'
MYLK	5'-CCCAGAGTTGTCTGGTTCAA-3'	5'-GCAGGTGTACTTGGCATCGT-3'
PAK6	5'-ACCAGCACTTCAACGTGGTG-3'	5'-GACTTGGGAGACGATGTCTGT-3'
BCL-2	5'-GGTGGGGTCATGTGTGTGG-3'	5'-CGGTTCAAGTACTCAGTCATCC-3'
MAPK10	5'-CAGATGGAATTAGACCATGAGCG-3'	5'-TCAATGTGCAATCAGACTTGACT-3'
CAV1	5'-GCGACCTAAACACCTCAAC-3'	5'-ATGCCGTCAAACTGTGTGTC-3'
VAV1	5'-CAACCTGCGTGAGGTCAAC-3'	5'-ACCTTGCCAAAATCCTGCACA-3'
TNC	5'-TCCCAGTGTTCCGGTGGATCT-3'	5'-TTGATGCGATGTGTGAAGACA-3'
PTK2	5'-AGTGGACCAGGAAATTGCTTTG-3'	5'-GTGTTTTGGCCTTGACAGAATC-3'
KLK3	5'-GTGTGTGGACCTCCATGTTATT-3'	5'-CCACTCACCTTTCCCTCAAG-3'

Table S2. The list of antibodies used in this study.

Antibody	Source	Identifier
MYO6	Proteintech	26778-1-AP
AR	Abcam	ab108341
H3K27Ac	CST	8173
Ki-67	Abcam	ab16667
FAK	CST	71433
pFAK	CST	8556
ITGA9	Abclonal	A14007
ITGB8	Abclonal	A8433
Vimentin	Proteintech	10366-1-AP
Snai1	Proteintech	13099-1-AP
E-cadherin	Proteintech	20874-1-AP
N-cadherin	Proteintech	22018-1-AP
Caspase-3	Proteintech	19677-1-AP
BCL-2	Proteintech	26593-1-AP
VEGFA	Proteintech	19003-1-AP
GAPDH	Proteintech	60004-1-Ig
BAX	Proteintech	50599-2-Ig